wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

Endogolix

Total questions: 15

Worksheet time: 8mins

Name
Class
Date
1.

Tissue that normally lines the inside of the uterus grows in places other than the uterus, such as:

a)

Ovaries

b)

Fallopian tubes

c)

Bowel/ bladder

d)

Rectum

2.

endometriosis is an --------- dependent chronic inflammatory disease

(a)  

3.

Endometriosis causes are

a)

Retrograde Menstruation

b)

Alcohol & Smoking

c)

Celomatic Metaplasia

d)

Lymphatic & Vascular Metaplasia

4.

Three distinct forms of endometriosis are:

a)

Peritoneal

b)

Vaginal

c)

Seminal vesicle

d)

Recto-vaginal

5.

Endometriosis has the following clinical presentations:

a)

dysmenorrhea

b)

dyspareunia

c)

non-menstrual pelvic pain

d)

pregnancy

6.

Signs & symptoms of endometriosis

a)

Infertility

b)

Pain, menstrual cramps, heavy bleeding

c)

Dyspareunia

d)

Fatigue

e)

Diarrhea, constipation & /or low back pain, nausea

7.

What are the medical management options available for endometriosis?

a)

Combined OC pills

b)

Progestins (dinogest/dydrogesterone)

c)

GnRH agonist

d)

GnRH antagonist

e)

Aromatase inhibitors

8.

Shortcomings of OC pills/ Progesterone

a)

33% symptomatic patients are

non-responders

b)

Efficacy decreases over time

c)

Side effects such as weight gain, mood swings, irregular uterine bleeding

d)

Venous/ arterial embolism

9.

Shortcomings of Progastrin-only formulations

a)

progesterone resistance

b)

drug-induced breakthrough bleeding

c)

permanent decreases in BMD

d)

limited efficacy

10.

Shortcomings of GnRH Agonists (Leuprorelin, Goserelin, Triptorelin)

a)

Flare-up effect

b)

Excessive suppression / inability to titrate E2 levels

c)

Unpredictable reversibility of the treatment

d)

Side effects such as hot flushes / BMD loss

11.

Main Advantages of GnRH antagonists such as Elagolix

a)

Immediate gonadotropin suppression.

No flare-up effect.

b)

Dose-dependent estrogen suppression.

c)

Rapid reversibility & recovery of hormone secretion after stopping the treatment.

d)

Possibility of individual dose tailoring to balance efficacy and safety.

12.

Elagolix received approval from the US FDA in 2018 and the DCGI in 2024.

a)

True

b)

False

13.

Elagolix is available in 2 SKU forms: 150 mg and 200 mg.

a)

True

b)

False

14.

The dosage of Elagolix is 150 mg once daily for 24 months or 200 mg twice daily for 6 months.

a)

True

b)

False

15.

Advantages of Elagolix

a)

Oral agent, titratable estrogen suppression, which is not possible with injectable GnRH agonists.

b)

Individual treatment based on tolerability and clinical presentation.

c)

Does not suppress normal endometrium.

d)

Does not completely suppress ovulation.

e)

Appropriate empiric therapy for endometriosis.